Abstract
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, is associated with a broad spectrum of post-infectious dermatologic sequelae, among which diffuse hair loss—most commonly telogen effluvium (TE)—is increasingly recognized. Hair follicle dysfunction appears to result from a convergence of systemic inflammation, cytokine-mediated follicular cycling disruption, hypoxic stress, and metabolic reprogramming of keratinocytes. Emerging molecular studies also suggest potential direct viral interaction with follicular epithelial structures. This review synthesizes current evidence regarding the pathophysiology, protein-level alterations, clinical presentation, and management strategies for COVID-19–associated hair disorders.
1. Introduction: Hair Follicles as a Dynamic Immunometabolic Organ
The human hair follicle is not merely a keratin-producing appendage but a highly active immunologically privileged mini-organ with cyclical phases of growth (anagen), regression (catagen), and rest (telogen). Disruption of this cycle can result in diffuse shedding or structural alopecia.
COVID-19 has been associated primarily with telogen effluvium, a condition characterized by premature transition of hair follicles into the telogen phase following systemic stressors.¹
Unlike scarring alopecias, TE is typically reversible; however, COVID-19 appears to produce a more synchronized and abrupt follicular shift, suggesting a distinct inflammatory or metabolic trigger compared with classic stress-induced TE.
2. Hair Cycle Physiology and Vulnerability to Systemic Disease
2.1 Anagen phase (growth)
During anagen, follicular keratinocytes undergo rapid proliferation requiring:
- high oxygen availability
- robust mitochondrial ATP production
- tightly regulated Wnt/β-catenin signaling
Any systemic disturbance affecting energy metabolism or inflammatory signaling can prematurely terminate this phase.
2.2 Catagen phase (regression)
Catagen is driven by:
- apoptosis of matrix keratinocytes
- reduced dermal papilla signaling
- increased TGF-β activity
COVID-19–associated cytokine storms may accelerate catagen entry.²
2.3 Telogen phase (rest)
Telogen follicles remain quiescent until reactivation. A large proportion entering telogen simultaneously results in diffuse shedding 2–3 months later.
3. Telogen Effluvium as the Dominant COVID-19 Hair Disorder
Multiple systematic reviews confirm TE as the most common post-COVID alopecia phenotype.³
Key clinical characteristics include:
- diffuse non-scarring shedding
- onset 1–3 months post infection
- female predominance (~70–85%)
- high reversibility (>90%) within 6 months in most cohorts⁴
This pattern is consistent with systemic physiological stress rather than localized follicular disease.
4. Systemic Inflammatory Mechanisms
4.1 Cytokine storm–mediated follicular arrest
COVID-19 is characterized by elevated:
- IL-6
- TNF-α
- IL-1β
- interferon signaling pathways
These cytokines directly influence follicular cycling by:
- suppressing Wnt signaling (anagen maintenance)
- promoting premature catagen entry
- altering dermal papilla signaling integrity
IL-6 in particular has been shown to inhibit epithelial proliferation in multiple keratinized tissues.⁵
4.2 Autoimmune activation hypothesis
Post-viral immune dysregulation may lead to:
- transient loss of follicular immune privilege
- increased CD8+ T-cell infiltration
- autoimmune-like follicular stress responses
This may explain prolonged or relapsing shedding in long COVID patients.
5. Vascular and Hypoxic Contributions
SARS-CoV-2–induced endothelial dysfunction contributes to:
- microvascular hypoperfusion of hair follicles
- reduced dermal papilla oxygenation
- impaired nutrient delivery
Histopathologic evidence demonstrates widespread endothelial inflammation in COVID-19 systemic disease.⁶
Hypoxia further induces:
- HIF-1α upregulation
- metabolic suppression of follicular stem cells
- mitochondrial dysfunction in rapidly dividing matrix keratinocytes
6. Direct Viral and Molecular Follicular Effects
Recent ex vivo studies have demonstrated:
- ACE2 and TMPRSS2 expression in hair follicle structures
- potential viral spike protein presence in follicular epithelium⁷
This raises the possibility of:
- direct follicular epithelial infection
- local immune activation within follicular units
- disruption of stem cell niches in the bulge region
Although still under investigation, this mechanism may explain more severe or persistent cases.
7. Protein-Level and Molecular Changes in Hair Follicles
COVID-19–associated follicular stress induces measurable molecular changes:
7.1 Keratin alterations
- reduced K31/K86 keratin expression
- altered hair shaft structural integrity
7.2 Growth signaling disruption
- downregulation of β-catenin pathway
- increased TGF-β and FGF suppression
7.3 Stress-response proteins
- increased heat shock proteins (HSP70)
- oxidative stress markers (ROS accumulation)
7.4 Proteoglycan and extracellular matrix changes
Systemic inflammation alters dermal papilla extracellular matrix composition, affecting follicle anchoring and cycling stability.⁸
8. Clinical Phenotypes of COVID-19–Associated Hair Loss
8.1 Acute telogen effluvium
- diffuse shedding
- onset ~2 months post infection
- self-limited in majority
8.2 Chronic telogen effluvium
- prolonged shedding beyond 6 months
- often associated with persistent systemic inflammation or long COVID
8.3 Anagen effluvium (rare)
- seen in severe systemic illness
- rapid hair loss during active disease phase
8.4 Mixed inflammatory alopecia
- overlap with androgenetic alopecia unmasking
- inflammatory scalp involvement in subset of patients
9. Clinical Course and Prognosis
A systematic review of COVID-associated TE demonstrated:
- median onset: ~2 months post infection
- median duration: ~5 months
- resolution rate: ~90–95% in most cohorts⁹
However, a subset of patients reports persistent shedding beyond 12–24 months, particularly in long COVID populations.
10. Diagnostic Evaluation
Recommended evaluation includes:
- ferritin and iron studies
- thyroid function testing
- vitamin D levels
- inflammatory markers (CRP, ESR)
- dermatologic examination with trichoscopy
Scalp biopsy is rarely required unless scarring alopecia is suspected.
Footnotes (Vancouver Style — Part I)
- Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015.
- Paus R, Cotsarelis G. The biology of hair follicles. N Engl J Med. 1999.
- Mieczkowska K et al. Hair loss in COVID-19 patients. J Am Acad Dermatol. 2021.
- Starace M et al. Post-COVID telogen effluvium. Dermatol Ther. 2020.
- Del Valle DM et al. Cytokine profiles in COVID-19. Nat Med. 2020.
- Ackermann M et al. Vascular pathology in COVID-19. N Engl J Med. 2020.
- Klingenstein S et al. Spike protein in hair follicles. Sci Rep. 2025.
- Rossi A et al. Telogen effluvium mechanisms in SARS-CoV-2 infection. Skin Appendage Disord. 2021.
- Gupta AK et al. COVID-19 hair loss systematic review. J Eur Acad Dermatol Venereol. 2021.
- Hussain N et al. Acute telogen effluvium post COVID-19. J Med Virol. 2021.
- Rebora A. Telogen effluvium pathophysiology. Dermatology. 2010.
- Trüeb RM. Stress and hair loss. Exp Dermatol. 2009.
- Li Y et al. Hair follicle immune privilege. J Invest Dermatol. 2019.
- Stenn KS, Paus R. Controls of hair follicle cycling. Physiol Rev. 2001.
- WHO COVID-19 Clinical Characterization Consortium. Lancet. 2020.
- Daneshgaran G et al. Dermatologic COVID-19 manifestations. Dermatol Ther. 2020.
- Vabres P et al. Hair cycle inflammatory regulation. Br J Dermatol. 2018.
- Fabbrocini G et al. Hair disorders review. Dermatol Clin. 2019.
- Tobin DJ. Hair follicle immunology. Exp Dermatol. 2017.
- Semenza GL. Hypoxia signaling pathways. Cell. 2012.
- Wnt/β-catenin signaling in hair growth regulation. Nature. 2015.
- Cotsarelis G. Stem cells in hair follicles. Science. 1990.
- Sperling LC. Telogen effluvium diagnosis. J Am Acad Dermatol. 2000.
- Messenger AG. Hair cycle disorders. Clin Dermatol. 2013.
- Sinclair R. Diffuse alopecia mechanisms. Australas J Dermatol. 2015.